Six-Gene Mitophagy Signature Predicts Liver Cancer Survival and Treatment Response
A mitophagy-based gene score stratifies hepatocellular carcinoma patients by prognosis, immune status, and chemotherapy sensitivity.
Summary
Researchers identified a six-gene signature tied to mitophagy — the cellular process of recycling damaged mitochondria — that predicts survival outcomes in liver cancer patients. Using data from two large tumor databases, they scored patients on a mitophagy enrichment index and found those with higher scores had more than double the risk of death. The six-gene panel (ACTR6, GAPDH, ATIC, ANP32E, CCT6A, BSG) predicted one-, three-, and five-year survival with reasonable accuracy. High-risk patients showed suppressed immune activity and different responses to chemotherapy drugs. Single-cell analysis revealed mitophagy activity was especially high in proliferating immune cells within tumors. These findings could eventually guide treatment decisions and help identify which liver cancer patients need more aggressive therapy.
Detailed Summary
Hepatocellular carcinoma (HCC) is one of the most lethal cancers globally, with poor prognosis largely because it is often diagnosed late and responds inconsistently to treatment. Better molecular tools to stratify patients by risk and predict therapy response are urgently needed. Mitophagy — the selective autophagy-mediated clearance of damaged mitochondria — has emerged as a key player in tumor biology, influencing both cancer progression and resistance to treatment, yet its specific role in HCC prognosis has been poorly characterized until now.
This study used multi-omics data from the TCGA-LIHC and GSE14520 cohorts to systematically evaluate mitophagy-related genes in HCC. Researchers identified 20 differentially expressed mitophagy-related genes with prognostic value and used consensus clustering to divide patients into two biologically distinct groups with significantly different survival outcomes. A mitophagy enrichment score (MIES) was then derived using single-sample gene set enrichment analysis.
Patients with elevated MIES faced more than twice the mortality risk (HR = 2.17, p = 0.005) and showed signs of metabolic activation, immune suppression, and altered drug sensitivity. Single-cell analysis of the GSE140228 dataset revealed that mitophagy activity was highest in proliferating T cells and dendritic cells within the tumor microenvironment — key immune populations that influence cancer control and immunotherapy response.
A six-gene prognostic signature — comprising ACTR6, GAPDH, ATIC, ANP32E, CCT6A, and BSG — was constructed using LASSO-Cox regression. This model achieved one-, three-, and five-year AUCs of 0.780, 0.682, and 0.690, respectively. Laboratory validation confirmed upregulation of four of the six genes in HCC cell lines.
These findings position mitophagy as a clinically meaningful axis in liver cancer biology. If validated prospectively, this scoring system could inform treatment stratification and highlight new therapeutic targets in HCC. Limitations include the retrospective, bioinformatic design and the need for prospective clinical validation.
Key Findings
- High mitophagy enrichment score (MIES) more than doubled mortality risk in liver cancer patients (HR = 2.17).
- A six-gene panel predicted 1-, 3-, and 5-year survival with AUCs of 0.780, 0.682, and 0.690.
- High-risk patients showed immune suppression and distinct chemotherapy sensitivity profiles.
- Mitophagy activity was highest in proliferating T cells and dendritic cells in the tumor microenvironment.
- Four of six signature genes (ACTR6, CCT6A, ATIC, BSG) were experimentally confirmed upregulated in HCC cells.
Methodology
The study analyzed gene expression data from the TCGA-LIHC and GSE14520 cohorts, applying consensus clustering, ssGSEA scoring, and LASSO-Cox regression to develop and validate a six-gene prognostic model. Single-cell RNA sequencing data from GSE140228 was used to map mitophagy activity across tumor cell populations. Laboratory qPCR validation of gene expression was performed in HCC cell lines.
Study Limitations
This summary is based on the abstract only, as the full paper was not available. The study is entirely retrospective and bioinformatic; no prospective clinical cohort was used to validate the signature. Laboratory validation was limited to qPCR in cell lines, and functional mechanistic studies confirming causal roles of the six genes are lacking.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: